氨酸抑制可以防止由来自大脑的寡合体引起的突触可塑性缺陷
Pietro Scaduto1, Michela Marcatti1, Nemil Bhatt1
1Department of Neurology, Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch (UTMB), 301 University Blvd, Galveston, TX 77555, USA.
Brain communications
|September 6, 2024
概括
FK506 (tacrolimus) 通过阻断有毒的寡聚体和恢复突触功能来治疗阿尔茨海默病. 这种免疫抑制剂在保护对认知衰退和突触可塑性损失方面表现有前途.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 涉及陶蛋白聚合,形成有毒的寡合体,损害了突触可塑性.
- 寡合体毒性的确切机制尚不清楚.
- 美国食品和药物管理局批准的氨素抑制剂FK506 (tacrolimus) 已显示,患者的AD发病率有所降低.
研究的目的:
- 调查FK506的潜力,以抵消来自大脑的寡合体对突触可塑性的有毒影响.
- 在阿尔茨海默氏症病理背景下,探索FK506对突触mRNA水平的影响.
主要方法:
- 电生理学记录以评估突触可塑性.
- RNA测序以分析基因表达变化.
- 从阿尔茨海默病患者中分离和分析来自大脑的陶寡合物.
主要成果:
- FK506有效地阻断了寡合体对突触可塑性的急性神经毒性作用.
- 治疗FK506导致恢复特定的关键突触信使RNA (mRNA) 水平.
- 有证据表明,FK506可以缓解陶诱导的突触功能障碍.
结论:
- FK506显示出作为阿尔茨海默病治疗剂的潜力.
- 该药物的机制涉及保护突触可塑性免受寡合体毒性的作用.
- 进一步的研究支持FK506用于新的阿尔茨海默氏症治疗策略.
相关概念视频
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
110
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
110
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K


